CN106919801B - Immunohistochemical staining auxiliary analysis system and use method - Google Patents

Immunohistochemical staining auxiliary analysis system and use method Download PDF

Info

Publication number
CN106919801B
CN106919801B CN201710133740.6A CN201710133740A CN106919801B CN 106919801 B CN106919801 B CN 106919801B CN 201710133740 A CN201710133740 A CN 201710133740A CN 106919801 B CN106919801 B CN 106919801B
Authority
CN
China
Prior art keywords
tumor
antigen
detected
tumors
analysis system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710133740.6A
Other languages
Chinese (zh)
Other versions
CN106919801A (en
Inventor
夏成青
陈红梅
杨德宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Daga Information Technology Co ltd
Original Assignee
Hangzhou Daga Information Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Daga Information Technology Co ltd filed Critical Hangzhou Daga Information Technology Co ltd
Priority to CN201710133740.6A priority Critical patent/CN106919801B/en
Publication of CN106919801A publication Critical patent/CN106919801A/en
Application granted granted Critical
Publication of CN106919801B publication Critical patent/CN106919801B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

The invention discloses an immunohistochemical staining auxiliary analysis system and a use method thereof, wherein the analysis system can call stored theoretical data and pathological data, and calculate and compare the stored theoretical data and pathological data to be called: theoretical data and pathology data; the theoretical data comprises antigen information of known various tumors, wherein the antigen information of each tumor comprises the expression positive rate corresponding to various antigens in the tumor; the pathology data comprises the detected positive expression rate of the antigens in the unknown tumor and the detected positive or negative information of the antigens in the unknown tumor.

Description

Immunohistochemical staining auxiliary analysis system and use method
Technical Field
The invention relates to a medical data analysis auxiliary system, in particular to an immunohistochemical staining auxiliary analysis system and a use method thereof.
Background
In daily work, some tumors cannot be distinguished by conventional HE staining, and need to be distinguished by immunohistochemical staining. The common practice is as follows: depending on morphology, several tumors requiring differential diagnosis, such as tumor A, B, C, were proposed, at which time we selected antibodies (as opposed to antigens, which bind specifically to antigens). The principle of antibody selection is that the more differential the more valuable the identification is, the inconsistent antigen is expressed in the tumor to be identified. The tumor types are various, and the antigen information corresponding to each tumor is rich, so when a large amount of information is processed, the information package formed by the plurality of antigen information combined together is needed to find the type of the tumor with high probability so as to assist the final diagnosis of the tumor, or the auxiliary information is provided to assist in screening which antigens are preferentially checked, so that the final diagnosis can be assisted.
Disclosure of Invention
The invention overcomes the defects of the prior art and provides an immunohistochemical staining auxiliary analysis system and a use method thereof.
In order to achieve the above purpose, the first technical scheme adopted by the invention is as follows: an immunohistochemical staining-assisted analysis system, wherein the analysis system is capable of recalling stored theoretical data and pathology data, and calculating an alignment recalled: theoretical data and pathology data;
the theoretical data comprises antigen information of known various tumors, wherein the antigen information of each tumor comprises the expression positive rate corresponding to various antigens in the tumor;
the pathology data comprises the detected positive expression rate of the antigens in the unknown tumor and the detected positive or negative information of the antigens in the unknown tumor.
The second technical scheme adopted by the invention is as follows: a method of screening an antigen to be detected using an analytical system, characterized in that:
step I), inputting the N kinds of pre-judged tumor names into the analysis system;
step II) the analysis system invokes all antigen information in each pre-judged tumor, calculates the difference value of the expression positive rate of each identical antigen coexisting in any two tumors, sorts the difference value according to the size, and forms a group of sorting for each two tumors in the N pre-judged tumors to form N groups of sorting altogether;
step III) selecting at least one antigen with the largest difference value from each group of sequences formed in step II) as an antigen to be detected.
The third technical scheme adopted by the invention is as follows: a method for performing an unknown tumor analysis using an analysis system, comprising:
step a), detecting a plurality of detected antigens aiming at unknown tumors, and analyzing whether each detected antigen is negative or positive;
step b) taking the expression positive rate values of a plurality of detected antigens corresponding to each tumor, and calculating the integral of each tumor according to the following formula:
X＝(T 1 *k 1 )+(T 2 *k 2 )+...+(T n *k n ) Wherein the method comprises the following steps:
y is the integral of the tumor;
T n the positive rate value of the expression of the detected antigen;
K n for the determination of the coefficient, if the antigen to be detected is positive, k n =1; if detected againstOriginal negative, then k n ＝-1；
Step c) ranks all tumor scores, the higher the score, the higher the likelihood that the corresponding tumor diagnosis will be true.
The fourth technical scheme adopted by the invention is as follows: a method for performing an unknown tumor analysis using an analysis system, comprising:
step 1) detecting a plurality of detected antigens aiming at unknown tumors, and analyzing whether each detected antigen is negative or positive;
step 2) taking the expression positive rate values of a plurality of detected antigens corresponding to each tumor, and calculating the integral average value of each tumor according to the following formula:
wherein:
y is the integral average of the tumor;
J n the integral corresponding to the expression positive rate value of the detected antigen;
K n for the determination of the coefficient, if the antigen to be detected is positive, k n =1; if the antigen detected is negative, k n ＝-1；
Step 3) sorting all the tumor integral average values, wherein the higher the integral average value is, the higher the probability of establishment of corresponding tumor diagnosis is.
In a preferred embodiment of the invention, a plurality of intervals in which the numerical value of the expression positive rate is distributed in sequence from small to large are divided according to the numerical value of the expression positive rate, each interval corresponds to an integral, and the sizes of the integral are also distributed from small to large.
In a preferred embodiment of the present invention, the correspondence between the expression positive rate and the integral is as shown in the following table,
expression Positive Rate (%) Integration (T) n )
100 6
95-99.9 5
85-94.9 4
75-84.9 3
65-74.9 2
55-64.9 1
45-54.9 0
35-44.9 -1
25-34.9 -2
15-24.9 -3
5-14.9 -4
0.1-4.9 -5
0 -6
It should be noted in particular that:
(1) The immunohistochemical staining auxiliary analysis system is a software data processing system based on computer technology, and is not a disease diagnosis method.
(2) The method for screening the antigen to be detected by using the analysis system can only assist in checking down detection items aiming at tumors, such as detecting as few antigen types as possible, can assist doctors in reducing the workload and improving the working efficiency of the doctors, and is a method for directly acquiring information serving as an intermediate result.
(3) The method for analyzing unknown tumor by using the analysis system can only assist in diagnosing tumor or reduce the range of tumor diagnosis, but can not directly determine the diagnosis result of the tumor. The result obtained according to the method is not a final diagnosis result, and after further obtaining the result according to the method, it is possible for the doctor to obtain the diagnosis result finally only by further analyzing and checking based on the result obtained according to the method.
The invention solves the defects existing in the background technology, and has the following beneficial effects: through the established tumor information and antigen information database corresponding to each tumor, doctors can be assisted to inquire and search the tumor information and the antigen information, and through the electronization of the information, the work efficiency of the doctors can be better improved, the speed is reduced, various information is inquired and calculated, and diagnosis is assisted.
Detailed Description
The present invention will now be described in further detail with reference to examples.
The first technical scheme is as follows: an immunohistochemical staining-assisted analysis system capable of recalling stored theoretical data and pathology data, and calculating an alignment recalled: theoretical data and pathology data;
the theoretical data comprises antigen information of known various tumors, wherein the antigen information of each tumor comprises the expression positive rate corresponding to various antigens in the tumor;
the pathology data includes the positive rate of expression of the detected antigens in the unknown tumor and information of whether the antigens are positive or negative in the unknown tumor.
Through the established tumor information and antigen information database corresponding to each tumor, doctors can be assisted to inquire and search the tumor information and the antigen information, and through the electronization of the information, the work efficiency of the doctors can be better improved, the speed is reduced, various information is inquired and calculated, and diagnosis is assisted.
The second technical proposal is as follows: a method for screening an antigen to be detected using an analytical system,
step I), inputting the N kinds of pre-judged tumor names into the analysis system;
step II) the analysis system invokes all antigen information in each pre-judged tumor, calculates the difference value of the expression positive rate of each identical antigen coexisting in any two tumors, sorts the difference value according to the size, and forms a group of sorting for each two tumors in the N pre-judged tumors to form N groups of sorting altogether;
step III) selecting at least one antigen with the largest difference value from each group of sequences formed in step II) as an antigen to be detected.
In general, the same kind of antigen can exist in different kinds of tumors, but the expression positive rate of the antigen in different tumors is different, if the different performances are particularly obvious, namely, the difference of the expression positive rate is relatively large, the detection of the antigen has value for differential diagnosis of different tumors, so that when selecting which antigens to detect, an effective method for screening the antigen to be detected is provided, and the blindness of detection is avoided.
The second technical scheme involves antigen selection and detection, wherein the antigen selection is to identify two or more kinds of tumors, and mainly to see that the tumor antigen expression difference is not high in selection positive rate, but large in selection positive rate. Therefore, positive and negative are distinguished when the integral is performed, and even if the positive rate is 0, the solid test result is negative, the highest integral is 6 minutes.
The method of the second technical scheme can assist doctors to find out the optimal examination scheme, and the doctors can select antigens to be detected in a targeted manner through analysis results (sequencing information) provided by the method. By this method, a doctor can quickly determine an examination plan and examination items in a short time, shortening the time for the treatment of a patient.
The third technical scheme is as follows: a method for performing an unknown tumor analysis using an analysis system,
step a), detecting a plurality of detected antigens aiming at unknown tumors, and analyzing whether each detected antigen is negative or positive;
step b) taking the expression positive rate values of a plurality of detected antigens corresponding to each tumor, and calculating the integral of each tumor according to the following formula:
X＝(T 1 *k 1 )+(T 2 *k 2 )+...+(T n *k n ) Wherein:
y is the integral of the tumor;
T n the positive rate value of the expression of the detected antigen;
K n for the determination of the coefficient, if the antigen to be detected is positive, k n =1; if the antigen detected is negative, k n ＝-1；
Step c) ranks all tumor scores, the higher the score, the higher the likelihood that the corresponding tumor diagnosis will be true.
On the basis of the third technical scheme, a fourth technical scheme is further provided as follows: a method for performing an unknown tumor analysis using an analysis system,
step 1) detecting a plurality of detected antigens aiming at unknown tumors, and analyzing whether each detected antigen is negative or positive;
step 2) taking the expression positive rate values of a plurality of detected antigens corresponding to each tumor, and calculating the integral average value of each tumor according to the following formula:
wherein:
y is the integral average of the tumor;
J n the integral corresponding to the expression positive rate value of the detected antigen;
K n for the determination of the coefficient, if the antigen to be detected is positive, k n =1; if the antigen detected is negative, k n ＝-1；
Step 3) sorting all the tumor integral average values, wherein the higher the integral average value is, the higher the probability of establishment of corresponding tumor diagnosis is.
Dividing a plurality of intervals in which the values of the expression positive rate are distributed in sequence from small to large according to the values of the expression positive rate, wherein each interval corresponds to an integral, the integral is also distributed from small to large, the correspondence between the expression positive rate and the integral is as shown in the following table,
the difference of each range can be enlarged by integrating the expression positive rate one by one, so that the data analysis is more explicitly shown.
Through the third technical scheme and the fourth technical scheme, doctors can quickly find the most possible tumor types by means of an analysis system based on limited antigen information, and the doctors are assisted in further diagnosis. It is stated that the results obtained by the analysis system according to the third and fourth technical solutions are not the final diagnosis results or health conditions, but are intermediate information of the diagnosis process, and the doctor needs to further and more specifically diagnose the problems related to the subsequent process through the above information.
The above-described preferred embodiments according to the present invention are intended to suggest that, from the above description, various changes and modifications can be made by the person skilled in the art without departing from the scope of the technical idea of the present invention. The technical scope of the present invention is not limited to the description, but must be determined according to the scope of claims.

Claims (1)

1. An immunohistochemical staining auxiliary analysis system, characterized in that the analysis system can call stored theoretical data and pathological data, and calculate and compare the called theoretical data and pathological data;
the theoretical data comprises antigen information of known various tumors, wherein the antigen information of each tumor comprises the expression positive rate corresponding to various antigens in the tumor;
the pathology data comprises positive or negative information of a plurality of antigens in unknown tumors;
screening antigens to be detected using the assay system comprises the steps of:
step I), inputting the N kinds of pre-judged tumor names into the analysis system;
step II) the analysis system invokes all antigen information in each pre-judged tumor, calculates the difference value of the expression positive rate of each identical antigen coexisting in any two tumors, sorts the difference value according to the size, and forms a group of sorting for each two tumors in N pre-judged tumors, and forms a plurality of groups of sorting;
step III), selecting at least one antigen with the largest difference value from each group of sequences formed in the step II) as an antigen to be detected;
the analysis of unknown tumors using the analysis system comprises the steps of:
step 1) detecting a plurality of detected antigens aiming at unknown tumors, and analyzing whether each detected antigen is negative or positive;
step 2) taking the expression positive rate values of a plurality of detected antigens corresponding to each tumor, and calculating the integral average value of each tumor according to the following formula:
Y=[(J 1 *k 1 )+(J 2 *k 2 )+…+(J n *k n )]/n
y is the integral average of the tumor;
J n the integral corresponding to the expression positive rate value of the detected antigen;
k n for the determination of the coefficient, if the antigen to be detected is positive, k n =1; if the antigen detected is negative, k n ＝-1；
Step 3) sorting the integral average values of all tumors, wherein the higher the integral average value is, the higher the possibility that the corresponding tumor diagnosis is established is;
dividing a plurality of intervals in which the numerical value of the expression positive rate is distributed in sequence from small to large according to the numerical value of the expression positive rate, wherein each interval corresponds to an integral, and the integral is also distributed from small to large; the positive expression rate ranges are 100%, 95-99.9%, 85-94.9%, 75-84.9%, 65-74.9%, 55-64.9%, 45-54.9%, 35-44.9%, 25-34.9%, 15-24.9%, 5-14.9%, 0.1-4.9%, and 0%; the integral corresponding to the expression positive rate interval is 6, 5, 4, 3, 2, 1, 0, -1, -2, -3, -4, -5 and-6 in sequence.
CN201710133740.6A 2017-03-08 2017-03-08 Immunohistochemical staining auxiliary analysis system and use method Active CN106919801B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710133740.6A CN106919801B (en) 2017-03-08 2017-03-08 Immunohistochemical staining auxiliary analysis system and use method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710133740.6A CN106919801B (en) 2017-03-08 2017-03-08 Immunohistochemical staining auxiliary analysis system and use method

Publications (2)

Publication Number Publication Date
CN106919801A CN106919801A (en) 2017-07-04
CN106919801B true CN106919801B (en) 2023-07-18

Family

ID=59460502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710133740.6A Active CN106919801B (en) 2017-03-08 2017-03-08 Immunohistochemical staining auxiliary analysis system and use method

Country Status (1)

Country Link
CN (1) CN106919801B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1695057A (en) * 2002-09-12 2005-11-09 摩诺根公司 Cell-based detection and differentiation of disease states
CN101598731A (en) * 2009-05-07 2009-12-09 陈志南 A kind of immunohistochemical diagnosis kit that is used for the pathologic diagnosis of tumor purposes
CN104969071A (en) * 2012-11-30 2015-10-07 应用蛋白质组学公司 Method for evaluation of presence of or risk of colon tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110106740A1 (en) * 2002-05-24 2011-05-05 University Of South Florida Tissue classification method for diagnosis and treatment of tumors
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
WO2012075069A2 (en) * 2010-12-02 2012-06-07 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with cancer and methods of use thereof
DK2914739T3 (en) * 2012-11-05 2017-11-27 Novigenix Sa COMBINATIONS OF BIOMARKERS FOR COLORECTAL TUMORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1695057A (en) * 2002-09-12 2005-11-09 摩诺根公司 Cell-based detection and differentiation of disease states
CN101598731A (en) * 2009-05-07 2009-12-09 陈志南 A kind of immunohistochemical diagnosis kit that is used for the pathologic diagnosis of tumor purposes
CN104969071A (en) * 2012-11-30 2015-10-07 应用蛋白质组学公司 Method for evaluation of presence of or risk of colon tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Specific Biomarkers: Detection of Cancer Biomarkers Through High-Throughput Transcriptomics Data;Wei Du等;《Cogn Comput》;20150528;第7卷;文章摘要，第657-658页，及图1 *

Also Published As

Publication number Publication date
CN106919801A (en) 2017-07-04

Similar Documents

Publication Publication Date Title
Biyani et al. Algorithms for red lesion detection in Diabetic Retinopathy: A review
Brandt et al. Recent taxonomic developments with Candida and other opportunistic yeasts
CN108511055A (en) Ventricular premature beat identifying system and method based on Multiple Classifier Fusion and diagnostic rule
CN110232360B (en) Method for judging negative and positive of fluorescent microscopic fungi by using neural network
Al-Hatmi et al. Rapid identification of clinical members of Fusarium fujikuroi complex using MALDI-TOF MS
CN112542247A (en) Method and system for predicting probability of complete remission of pathology after breast cancer neoadjuvant chemotherapy
CN113192064A (en) Esophageal cancer B3 type blood vessel identification method based on coefficient of variation method
CN106919801B (en) Immunohistochemical staining auxiliary analysis system and use method
TW201901621A (en) Method of generating image biomarkers for brain diseases
Elson et al. Automated extraction and analysis of retinal blood vessels with multi scale matched filter
Mamun et al. Recognition of human skin diseases using inception-v3 with transfer learning
Al-Gburi et al. Optical disk segmentation in human retina images with golden eagle optimizer
CN106801097A (en) Ring mediated isothermal amplification method based on the exclusive gene of plasmodium falciparum ring bodies
Sahoo et al. Detection of diabetic retinopathy from retinal fundus image using wavelet based image segmentation
Zhang et al. Blood vessel segmentation in fundus images based on improved loss function
CN113390853B (en) Method and system for identifying bacteria and fungi by using Raman spectrum
US8824769B2 (en) Process and system for analyzing the expression of biomarkers in a cell
CN109182495A (en) A kind of application method for the genetic chip of noninvasive antenatal detection bilateral Treating congenital cup ear, kit and genetic chip
CN115429284A (en) Electrocardiosignal classification method, electrocardiosignal classification system, computer equipment and readable storage medium
CN108588218A (en) A kind of minimally invasive detection kit of serum miRNA combination
CN111242968B (en) Method and system for detecting tooth area in tongue sample
US11535896B2 (en) Method for analysing cell-free nucleic acids
Sikkandar Automatic detection of genetics and genomics of eye disease using deep assimilation learning algorithm
CN108764360A (en) It is a kind of based on Symptom relativity to the analysis method of symptom dimensionality reduction
CN117554629B (en) Marker for differential diagnosis of neurosyphilis and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 404, Building 1818-2, Wenyi West Road, Yuhang Street, Hangzhou City, Zhejiang Province, 311100

Applicant after: Hangzhou Daga Information Technology Co.,Ltd.

Address before: Room E1056, Building 598 Guanghua Road, Minhang District, Shanghai 201100

Applicant before: SHANGHAI DAKA INFORMATION TECHNOLOGY CO.,LTD.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant